Compare CERT & KLRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CERT | KLRA |
|---|---|---|
| Founded | 2008 | 2024 |
| Country | United States | United States |
| Employees | 1576 | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2020 | 2026 |
| Metric | CERT | KLRA |
|---|---|---|
| Price | $9.35 | $11.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 6 |
| Target Price | $8.34 | ★ $42.40 |
| AVG Volume (30 Days) | ★ 2.0M | 944.6K |
| Earning Date | 11-05-2026 | 08-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.50 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $418,838,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.49 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.75 | N/A |
| 52 Week Low | $4.45 | $10.83 |
| 52 Week High | $13.88 | $23.82 |
| Indicator | CERT | KLRA |
|---|---|---|
| Relative Strength Index (RSI) | 67.06 | 30.94 |
| Support Level | $9.06 | N/A |
| Resistance Level | $10.04 | $19.15 |
| Average True Range (ATR) | 0.39 | 0.81 |
| MACD | 0.09 | -0.06 |
| Stochastic Oscillator | 96.76 | 11.85 |
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.